1- A. Rittmeyer, F. Barlesi, D. Waterkamp, et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, openlabel, multicentre randomised controlled trial, Lancet 389 (10066) (2017) 255–265.

2- A. Tunger, M. Kießler, R. Wehner, et al., Immune monitoring of cancer patients prior to and during CTLA-4 or PD-1/PD-L1 inhibitor treatment, Biomedicines 6 (1) (2018) 26.

3- D.S. Chen, B.A. Irving, F.S. Hodi, Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1, Clin. Cancer Res 18 (24) (2012) 6580–6587

4- D.B. Doroshow, S. Bhalla, M.B. Beasley, et al., PD-L1 as a biomarker of response to immune-checkpoint inhibitors, Nat. Rev. Clin. Oncol. 18 (6) (2021) 345–362.

 5- T.S.K. Mok, Y.L. Wu, I. Kudaba, et al., Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-smallcell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial, Lancet 393 (10183) (2019) 1819–1830

6- Lambin, P., Rios-Velazquez, E., Leijenaar, R., Carvalho, S., van Stiphout, R. G., Granton, P., et al. (2012). Radiomics: extracting more information from medical images using advanced feature analysis. Eur. J. Cancer 48 (4), 441–446. doi:10.1016/j.ejca.2011. 11.036

7- E.P. Huang, J.P.B. O’Connor, L.M. McShane, et al., Criteria for the translation of radiomics into clinically useful tests, Nat. Rev. Clin. Oncol. 20 (2) (2023) 69–82.